Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab cardiovascular risk in psoriasis
NCT05125679Phase 4Terminated
- Sponsor
- Janssen-Cilag
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 4 trial of guselkumab in plaque psoriasis, sponsored by Janssen-Cilag. Started Nov 2021; status: terminated.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05125679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125679.